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Abstract Since lithium inhibits IMPase and modulates phos- 
phatidylinositol (PtdIns) cell signalling at therapeutically relevant 
concentrations (0.5-1.0 mM), IMPase has attracted attention as 
a putative molecular target for lithium in the treatment of manic 
depression. IMPase is a homodimer, with each subunit organised 
in an a/]a/]ot arrangement of a-helices and /]-sheets, and this 
type of structure seems crucial to the two-metal catalysed mech- 
anism in which an activated water molecule serves as a nucleo- 
phile. Lithium appears to inhibit the enzyme following substrate 
hydrolysis by occupying the second metal binding site before the 
phosphate group can dissociate from its interaction with the site 
1 metal. The understanding of IMPase structure and the mecha- 
nism of substrate hydrolysis and lithium inhibition should be use- 
ful in the development of novel inhibitors which may prove clini- 
cally useful in the treatment of manic depression. 
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ium on signal transduction mechanisms, the modulation of the 
phosphatidylinositol (PtdIns)-linked cell signalling pathway 
(Fig. 1) has attracted most attention, primarily due to the fact 
that most of the effects of lithium on this pathway occur at 
therapeutically relevant concentrations of lithium (0.5-1.0 
raM). More specifically, it is proposed that lithium inhibits 
inositol monophosphatase (IMPase; a crucial enzyme in the 
recycling of inositol from the inositol polyphosphate s cond 
messengers (Fig. 1)), thereby causing adepletion ofinositol and 
consequently a reduced synthesis of PtdIns. This in turn ulti- 
mately results in an attenuation of the production of intracellu- 
lar second messengers in response to extracellular stimuli [6]. 
Consequently, IMPase is an attractive therapeutic target and 
accordingly has been subjected to detailed structural and mech- 
anistic analysis which will be reviewed in the present article. 
2. Sequence of inositol monophosphatase 
1. Inositol monophosphatase: Putative therapeutic target for 
lithium 
Although lithium (generally administered as lithium carbon- 
ate) is a very effective treatment for manic depression, it never- 
theless has appreciable side effects and a narrow range between 
therapeutic (0.5-1.0 raM) and toxic (>2 raM) plasma lithium 
concentrations [1]. Consequently, plasma lithium concentra- 
tions have to be monitored in patients receiving lithium ther- 
apy. Given these limitations, it is possible that compounds 
which mimic the mechanism of action of lithium might repre- 
sent novel treatments for manic depression that are devoid of 
the side effect and toxicity profile which may be due to millimo- 
lar concentrations of lithium interfering non-specifically with 
a number of key physiological functions (e.g. electrolyte 
homeostasis, ion transport, etc.). 
In order to try and develop compounds which mimic the 
therapeutic actions of lithium, it is first necessary to establish 
what the mechanism of action of lithium actually is. Unfortu- 
nately, although the use of lithium in the treatment of mania 
was described 46 years ago by the Australian physician John 
Cade [2], the mechanism by which lithium exerts its therapeutic 
effects remain unknown. Elucidating this mechanism of action 
is complicated by the diverse range of biochemical effects re- 
ported for lithium [3,4]. Recently, however, research as fo- 
cused on the role of lithium in the modulation of signal 
transduction mechanisms [4,5]. Of the variety of effects of lith- 
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Mammalian IMPase, which exists as a homodimer of subunit 
molecular weight of 30 kDa [7], has been purified and se- 
quenced from human, bovine and rat brain, and the amino acid 
sequence has been found to be 79% identical between these 
species [8]. In addition, mammalian IMPase shares 75% identity 
with frog IMPase [9]. However, despite being highly conserved 
between species the amino acid sequence of IMPase has very 
little overall identity with any known protein. 
Nevertheless, more restricted analyses how that regions of 
mammalian IMPase do share marked local similarity with other 
proteins (Fig. 2). More specifically, the importance of regions 
corresponding to IMPase amino acids 87-100, 21~233 and 
69-72 (motifs A, B and C, respectively) is indicated by the fact 
that not only do these regions contain most of the key amino 
acids involved in substrate and metal binding and nucleophile 
activation (i.e. Glu 7°, Asp 9°, Ile 92, Asp 93, Gly 94, Thr 95 and 
Asp 22°) but corresponding regions also occur in inositol poly- 
phosphate 1-phosphatase (IPP; a monomer of 400 amino acids 
which removes the 1-phosphate group from Ins(1,3,4)P 3 and 
Ins(1,4)P2) and fructose 1,6-bisphosphatase (F1,6-BP; a tetra- 
mer of subunit size 337 amino acids), both of which, like IM- 
Pase, are magnesium-dependent, lithium-sensitive nzymes 
with similar 2-metal catalysed mechanisms [10-14]. 
In addition to motifs A, B and C, which contain most of the 
key amino acids involved in substrate and metal binding and 
nucleophilic water activation, a region corresponding toamino 
acids 36-63 is also found in IPP. The fact that this region 
contains none of the key active site amino acids suggests that 
the secondary structure of this regions plays an important role 
in enzyme function. 
The occurrence of motifs A, B and C, as well as regions 
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Fig. 1. Simplified representation f the phosphatidylinositol (PtdIns) cell signalling pathway with second messenger molecules highlighted by boxes. 
Agonist-activated phospholipase C-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) produces the second messengers 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (Ins(l,4,5)P3), which activate protein kinase C and mobilise intracellular calcium, respectively. 
Whereas the recycling of DAG to the PtdIns precursor cytidine monophosphorylphosphatidate (CMP-PA) is relatively straightforward and proceeds 
via phosphatidic a id (PA), the metabolism of Ins(1,4,5)P3 is far more complex. Thus, Ins(1,4,5)P3 may be sequentially dephosphorylated o Ins(4)P 
or alternatively may be phosphorylated to Ins(1,3,4,5)P4 (which itself serves a second messenger function in calcium mobilisation) which is then 
sequentially dephosphorylated o Ins(1)P or Ins(3)E The final step in the recycling of inositol from the inositol polyphosphate s cond messengers 
is the dephosphorylation of the inositol monophosphates by IMPase. Consequently, in cells without appreciable uptake of extracellular inositol, 
IMPase plays a crucial role in the provision of inositol required to sustain this signalling pathway. 
corresponding to IMPase amino acids 36 63 in the qa-x protein 
of Neurospora crassa, the qutG protein of Aspergillus nidulans, 
the suhB and eysQ proteins ofE. coli. (the latter of which is also 
known as amtA) and the HAL2/MET22 gene of Saccharomyces 
cerevisiae [9,15-19] suggests that these proteins may be 
phosphatases. Moreover, some of these proteins (qa-X, qutG 
and suhB) also have conserved glutamates corresponding to 
Glu 213 [17], which is involved in substrate binding (see below). 
3. Structure of inositol monophosphatase 
In order to examine the three-dimensional structure of IM- 
Pase and to identify within the active site the key amino acids 
involved in substrate binding and the metal-catalysed substrate 
hydrolysis, crystals of IMPase were prepared for X-ray crystal- 
lographic examination. Although the most useful crystal struc- 
ture would have been an active form of the enzyme (i.e. with 
magnesium or manganese occupying metal-binding sites) with 
substrate bound in the active site, this was not possible since, 
by the very definition that the enzyme is active, the substrate 
would have been hydrolysed long before the several weeks 
required for growing of the crystals. Therefore, information 
was gathered from a number of crystal forms (Table 1). 
Each subunit of IMPase occurs as alternating ct-helix and 
fl-sheet secondary structures organised in a five-layered ~flo~flot 
sandwich. This ~fl~fl~ structure also occurs in F1,6-BP and an 
~flo~fl structure has been reported for IPP [10,12,14]. Thus, 
although there is a lack of overall sequence similarity between 
IMPase, IPP and F1,6-BP, and they occur as homodimer, mon- 
omer and homotetramer, respectively, the key feature of these 
enzymes that presumably confers their similar properties (i.e. 
phosphatase activity, magnesium-dependence a d inhibition by 
lithium) is their alternating ~-helical-fl-sheet t rtiary structure. 
Indeed, superimposition f the structures of these enzymes has 
identified a common core structure [12]. Furthermore, the re- 
gion of IMPase between amino acids 36-63, which although not 
containing any key amino acids is conserved between a number 
of proteins (Fig. 2), comprises one of the core structural ele- 
ments common to IMPase, IPP and F1,6-BP [12]. 
Table 1 
Summary of different IMPase crystal complexes 
Conditions and Comments 
resolution (A) 
No additional ligands 
(2.5) 
Gd3+/Li+/sulphate (2.1) 
Ca2÷/Li + (2.6) 
Gd3+/Li/Ins(1)P or 
Ins(3)P (2.2-2.3) 
Gd3+/Li+/inhibitor (2.8) 
Mn 2+ (2.6) 
Mn2+/phosphate (2.6) 
Apoenzyme. Information on overall structural 
features - no direct information on metal or 
substrate binding. 
Gd 3÷ binds at Mg 2÷ site 1, sulphate binds at 
phosphate-binding re ion, Li ÷ masks second 
metal-binding site. 9 metal igands. 
Confirms metal site 1 identified using Gd 3+. 
Enzyme inhibited by Gd 3÷, therefore no sub- 
strate turnover. Identifies amino acids puta- 
tively involved with substrate binding. 
Structure with phosphate-containing sub- 
strate-based inhibitor confirms binding infor- 
mation from substrate-enzyme structure. 
Structure in the presence of a metal that sup- 
ports catalysis. 3 metal sites identified. 
Structure in the presence of a metal that sup- 
ports catalysis. 2 metal sites identified. 
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1 Met-A•a-Asp-Pr•-Trp-G•n-G•u-Cys-Met-Asp-Tyr-A•a-va•-Thr-Leu-A•a-Arg-G•n-A•a-G•y- 20 
G3-PDH ~ 
21 G•u-Va•-Va•-Cys-G•u-A•a-I•e-Lys-Asn-G•u-Met-Asn-Va•-Met-Leu•Lys-Ser-Ser-Pr•-•a•- 40 
IPP, qa-x, qutG, suhB, cysQ, HAL2 
41 Asp-Leu-•a•-Tyr-A•a-Tyr-Asp-G•n-Lys-Va•-G•u-Lys-Met-Leu-I•e••er-Ser-I•e-Lys-G•u- 80 
63 69 MotlfC 
61 Lys-Tyr-Pro-Ser-His-Ser-Phe-Ile~Gly-Glu-Glu-Se~Val-Ala-Ala-Gly-Glu-Lys-Ser-Ile- 80 
87 Motif A 1~ 
81 Leu-Thr-Asp-Asn-Pro-ThrITrp-Ile-Ile-Asp-Pro-~le-Asp-Gly-Thr-Thr-Asn-Phe-Val-His ~ 100 
101 Arg-•he-•r•-Phe-Va•-A•a-Va•-Ser-I•e-G•y-Phe-A•a-Va•-Asn-Lys-Lys-I•e-G•u-•he-G•y- 120 
121 Va•-Va•-Tyr-Ser-Cys-Va•-G•u-G•y-Lys-Met-Tyr-Thr-A•a-Arg-Lys-G1y-Lys-G•y-A•a-Phe- 140 
G3-PDH 1~ 
141 Cys-Asn-Gly-Gln-Lys-Leu-Gln-Val-Ser-Gln-Gln-Glu Asp-Ile-Thr-Lys-Ser-Leu-Leu-Val- 160 
161 Thr-Glu-Leu-Gly-Ser-Ser-Arg-Thr-Pro-Glu-Thr-Val Arg-Met-Val-Leu-Ser-Asn-Met-Glu- 180 
m9 F1,6-BP 1~ 
181 Lys-Leu-Phe-Cys Ile-Pro-Val-His-Gly-Ile-Arg-Ser-Val-Gly-Thr-Ala-Ala-Val-Asn-Met- 200 
qa-x, qutG, suhB 219 
213 
201 Cys-Leu-Va~-A~a-Thr-G~y-G~y-A~a-Asp-A~a-Tyr-Tyr-G~u-Met-~y-I~e-His-Cys~Trp-Asp- 220 
Motif B 2~ 
221 Val-Ala-Gl~-Ala-Gly-Ile-Ile-Val-Thr-Glu-Ala-Gly-Gl~Val-Leu-Met-Asp-Val-Thr-Gly- 240 
241 G~y-Pr~-Phe-Asp-Leu-Met-Ser-Arg-Arg-Va~-I~e-A~a-A~a-Asn-Asn-Arg-I~e-Leu-A~a-G~u- 260 
261 Arg-Ile-Ala-Lys-Glu-Ile-Gln-Val-Ile-Pro-Leu-Gln-Arg-Asp-Asp-Glu-Asp 277 
Fig. 2. Sequence ofhuman inositol monophosphatase showing motifs A, B and C along with other egions of local sequence homology. Motifs A, 
B and C are found in inositol polyphosphate l-phosphatase (IPP) and fructose 1,6-bisphosphatase (F1,6-BP), indicating a key role for these regions 
in phosphatase activity. Moreover, the occurrence ofmotifs A, B and C in the qa-x protein of Neurospora crassa, the qutG protein of Aspergillus 
nidulans, and the suhB and eysQ (amtA) proteins of E. eoli, the salt tolerance (halotolerance) gene HAL2 of Saeeharomyees cerevisiae (which is 
identical to the methionine biosynthetic gene MET22) along with regions corresponding to IMPase amino acids 36-63 (also found in IPP) and in 
some cases Glu z~3, suggests hat these proteins, most of which are of unknown function, may possess phosphatase activity. Additional regions 
possessing homology to cytosolic glycerol 3-phosphate d hydrogenase (G3-PDH) (amino acids 19-28 and 137-148) and F1,6-BP (amino acids 
189-194) are also shown. Key amino acids involved in substrate (Asp 93, Gly 94 and Thr 95, Asp n° and Glu 2j3) and metal (Glu 7°, Asp 9°, Ile 92, Asp 93 and 
Asp n°) binding and enzyme mechanism (Glu 7° and, possibly, Thr 95) are highlighted inbold. The nomenclature of motifs A and B is consistent with 
that of Neuwald et al. [15]. 
4. Key active site interactions 
The structural determination f the IMPase active site per- 
mitted the identification fkey amino acids involved in putative 
metal binding, substrate binding and nucleophilic activation 
interactions (Fig. 3) and formed the framework for interpreting 
kinetic data derived from site-directed mutagenesis [20,21]. Al- 
though some of the key interactions were with the backbone 
rather than with the side chain of the amino acid (e.g. Ile 92, 
Gly 94, Thr 95 and Ala 196, in which case these interactions could 
not be studied by mutagenesis), most were with amino acid side 
chains (Table 2) and could be confirmed by mutagenesis [20,21]. 
In addition, in certain cases hypothesised interactions in IM- 
Pase could also be supported by evidence from IPP. For exam- 
ple, on the basis of kinetic data following site-directed mut- 
agenesis, the Thr 158 of IPP has been proposed to be involved 
in substrate binding and nucleophilic water activation [12] in 
a manner analogous to Thr 95 of IMPase [20,21]. 
4.1. Metal binding 
In the initial report of the structure of IMPase crystallised 
in the presence of gadolinium (Gd3+), sulphate (which mimics 
phosphate) and high lithium concentrations [17], and in a sub- 
sequent structure crystallised in the presence of Gd 3+, Ins(1)P 
or Ins(3)P and high lithium concentrations [22], only one metal 
(Gd3+)-binding site was identified. However, this proved some- 
what misleading since the higher valency of Gd 3+ involves an 
additional 2-3 metal binding ligands relative to Mn 2÷ and Mg 2+. 
For example, the Thr 95 and one of the two metaLsulphate 
interactions seen in the initial structure [17] were not observed 
in later crystals [22,23]. It was an unfortunate coincidence that 
lithium, which is commonly used in the growing of the crystals, 
was present since it probably occupied the second metal site in 
these crystals and could not be detected crystallographically. A 
subsequent s ructure determined in the presence of only Mn 2+ 
revealed the presence of 3 Mn 2+ in the active site, one of which 
(ligated by Glu 7°) was readily displaced upon phosphate bind- 
ing and was therefore unlikely to be involved in the enzyme 
mechanism [21]. The crystal structure showed that metal site 1 
was ligated by Glu TM, Asp 9° and Ile 92, although mutation of 
Glu 7° had little effect on metal binding, suggesting that the 
GluY°-metal 1 interaction was relatively weak [20]. Although 
the initial structural data had suggested only one (Gd3+)-metal 
binding site, the subsequent manganese or manganese plus 
4 J.R. Atack et al./FEBS Letters 361 (1995) 1-7 
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Table 2 
Summary of key substrate and metal binding and mechanistic interac- 
tions 
(A) Summary of involvement of individual amino acids 
Residue Involved in binding to: 
Glu 7° Site 1 metal, nucleophilic H20, site 3 metal 
Asp 9° Site 1 metal and site 2 metal 
Ile 92. Site 1 metal 
Asp 93 Site 2 metal and substrate 2-OH 
Gly 94. Substrate phosphate 
Thr 95. Substrate phosphate 
Thr 95 Nucleophilic H20 (possibly) 
Ala 196. Substrate 2-OH 
Glu 2~3 Substrate 4-OH 
Asp 22° Site 2 metal, substrate 6-OH 
(B) Ligands involved with specific functions 
Function Ligands involved and comments 
Substrate binding 
Inositol 
Phosphate 
Site 1 metal 
Site 2 metal 
Nucleophilic H20 
activation 
Lithium inhibition 
4-OH binds Glu 213. 
2-OH binds Asp 93 and Ala 196.. 
6-OH binds Asp 22°. 
Gly 94., Thr 95., site 1 metal, 2 waters, residues 
95-100 s-helix dipole. 
Glu 7°, Asp 9°, Ile 92., phosphate oxygen, 2solvent 
molecules. Binds before substrate and is required 
for subsequent substrate phosphate binding. Acti- 
vates H:O for nucleophilic attack on phosphate 
phosphorus. 
Asp 9°, Asp 93, Asp 22°, substrate ester oxygen, sub- 
strate 6-OH. Binds after substrate and acts as a 
Lewis acid to activate inositol ester oxygen. 
Site 1 metal, Glu 7° and, possibly, Thr 95. 
Binds to phosphate at site 2 metal following sub- 
strate hydrolysis. 
Functions of individual amino acids was supported by site-directed 
mutagenesis except for residues denoted by *, in which case interactions 
were with amide or carbonyl groups of the backbone and therefore 
could not be altered by mutagenesis. 
phosphate and structures clearly demonstrated a second metal- 
binding site which in conjunction with mutagenesis was shown 
to be ligated by Asp 9°, Asp 93 and Asp 22° [17,20-23]. 
4.2. Substrate binding 
Although the Gd3+-containing structures were somewhat 
misleading from a metal-binding point of view (because of the 
presence of lithium and the different valencies of Gd 3÷ and 
Mn 2÷ or Mg2+), they nevertheless provided useful information 
regarding substrate binding. Thus, since the enzyme was totally 
inhibited by Gd 3+, it was possible to obtain crystals of IMPase 
with substrate (Ins(1)P or Ins(3)P), as well as a substrate-based 
phosphate-containing inhibitor (2,4-dihydroxy inositol 1-phos- 
phate), and thereby identify key amino acids in the active site 
involved in substrate binding. Three hydroxyl groups in both 
Ins(1)P and Ins(3)P (the 2-, 4- and 6-OH of Ins(1)P) make 
4 hydrogen bond interactions with the enzyme, explaining the 
comparable affinity of the enzyme for these substrates [7], al- 
though the limited number of inositol hydroxyl-enzyme inter- 
actions explains the low affinity of the enzyme for inositol itself 
[24]. More specifically, the interactions between Ins(1)P and the 
enzyme are between the 2-OH and Asp 93 and Ala 196, 4-OH and 
Glu 213 and the 6-OH and Asp 22°. The substrate phosphate 
group is ligated by the backbone amides of Gly 94 and Thr 95 as 
well as the site 1 metal and 2 water molecules. In addition, the 
phosphate group is positioned at the base of an cz-helical dipole 
of residues 95-100 which also probably contributes to phos- 
phate binding. 
4.3. Nucleophilic water activation 
The nucleophilic water is activated by the site 1 metal, Glu 7° 
and, possibly, Thr 95. 
5. Mechanism 
The issue of whether the nucleophile involved in substrate 
hydrolysis is a water molecule or an active site amino acid 
residue has been unclear [24-27]. However, site-directed mut- 
agenesis has been used in conjunction with structural, kinetic 
and molecular modelling data to identify an activated water 
molecule rather than an amino acid as the nucleophile [21], in 
agreement with kinetic data which show the absence of a 
phospho-enzyme intermediate [24]. 
Initially, since enzyme structures were identified with either 
1, 2 or 3 metals present in the binding site, it was unclear how 
many metal ions participated in the enzyme mechanism. How- 
ever, direct experimental evidence from metal titration curves 
and molecular dynamics modelling of IMPase [21] clearly 
showed that a 2 (but not 1 or 3)-metal enzyme was consistent 
with observations derived from structure-activity relationships 
of substrate-based IMPase inhibitors [28] that the 6-OH of the 
substrate, which is important for the enzyme mechanism 
[21,29], co-ordinates the site 2 metal. These results implicat- 
ing 2 metals in the enzyme mechanism also help explain kinetic 
data [24,26,30,31]. Additional indirect evidence for a 2-metal 
mechanism of IMPase comes from the observation that 
both IPP and F1,6-BP also hydrolyse phosphate groups via a 
2-metal mechanism involving nucleophilic attack by water 
[12-14]. 
The proposed mechanism for IMPase is summarised in Fig. 
4. Briefly, the substrate (in this case Ins(1)P) binds with most 
of the binding energy being contributed by the substrate phos- 
phate group interacting with the site 1 metal. Next, the site 2 
metal binds and this permits the nucleophilic water to attack 
the substrate phosphorus. Inositol then debinds leaving phos- 
phate ligated to both metals. The site 2 metal then debinds and 
at this stage phosphate normally debinds from the site 1 metal, 
regenerating free enzyme ready for the next hydrolytic ycle. 
However, in the presence of lithium, the site 2 metal binding 
6-- 
Fig. 3. Substrate (Ins(1)P) is shown (in thick bonds) in the active conformation ofIMPase (i.e. with two magnesium ions/active site). This data could 
not be obtained irectly (Ins(1)P would have been hydrolysed by the catalytically active magnesium or manganese-containing enzyme) and is therefore 
an amalgamation f structural information obtained from the Gd3+-inhibited enzyme plus substrate and active enzyme minus substrate crystal 
structures (Pollack et al. [21]). Amino acid side chains with major oles in the active site are highlighted. The substrate r aches the active site through 
a channel that is roughly orientated in the direction shown by the arrow. 
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Fig. 4. Schematic representation f the mechanism of IMPase. (A) In the absence of substrate, a single magnesium ion is present in metal site (1). 
(B) Substrate (inositol 1-phosphate) binds with most of the energy of binding being contributed by the phosphate-magnesium interaction. (C) With 
substrate bound, a second magnesium ion occupies metal binding site (2). Binding of the second magnesium ion results in an activated water molecule 
attacking the phosphate phosphorus, resulting in cleavage ofthe phosphate bond. (D) After inositol debinds, phosphate is ligated by both magnesium 
ions. (E) The magnesium atmetal site (2) rapidly debinds resulting in an enzyme-phosphate complex in which the phosphate is ligated primarily 
to the metal site (1) magnesium. (F) Ordinarily, the phosphate rapidly debinds regenerating IMPase with one magnesium present ready for the next 
catalytic ycle. However, in the presence oflithium, the site (2) metal binding site becomes occupied by lithium and phosphate can no longer debind. 
The enzyme-magnesium-phosphate-lithium complex is then very stable and the enzyme is inhibited. 
site becomes occupied by lithium, essentially trapping the phos- 
phate group and thereby inhibiting the enzyme. 
6. Conclusions 
Structural, kinetic and site-directed mutagenesis data have 
been used to elucidate the mechanism of IMPase and have 
demonstrated a 2-metal catalysed hydrolysis of substrate. In 
this regard, IMPase is similar to F1,6-BP and IPE both of 
which are also magnesium-dependent phosphatases that are 
inhibited by lithium. As regards lithium inhibition, this proba- 
bly occurs after hydrolysis of the substrate as a consequence of 
lithium occupying the site 2 metal binding site and thereby 
forming a stable E. Mg 2+' phosphate. Li complex. 
Mutagenesis data and sequence comparisons with IPP and 
F1,6-BP show that key residues in motifs A, B and C are crucial 
to IMPase activity. However, there is very little sequence simi- 
larity outside of these regions and it is the tertiary structure 
rather than primary amino acid sequence that is the striking 
common feature of these enzymes. Thus, all three enzymes 
share a similar organisation ofa-helices and fl-sheets into alter- 
nating layers. 
Although substrate-based inhibitors have proved useful tools 
for evaluating the inositol depletion hypothesis by showing that 
IMPase inhibitors can mimic the effects of lithium on the PI 
signalling pathway in vitro [32], these compounds proved un- 
suitable for in vivo use [28]. In this regard, the combined mech- 
anistic and structural information on IMPase should prove 
useful in the development of novel inhibitors of this enzyme that 
may be of clinical utility in the treatment ofmanic depression. 
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